Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -97K | 0 | 0 | 0 | 0 |
| Operating Income | -68M | -82M | -40M | -45M | -36M |
| EBITDA | -68M | -30M | -40M | -45M | -36M |
| Net Income | -60M | -74M | -35M | -45M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$12.65
-0.78% today
1Y Change
+808.73%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Climb Biotherapeutics, Inc. (CLYM) is a Healthcare stock with a market cap of $780.00M and listed on NASDAQ. The stock last traded around $12.65 and up 808.7% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +42.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +42.5%, free cash flow -250.5% with operating margin 0.0% and ROIC -42.2%. Stock Foundry combines CLYM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLYM
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLYM Max Drawdown
-33.87%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CLYM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$47.5M
-4.9% YoY
Free Cash Flow
-$36.1M
+3.5% YoY
Revenue Growth
+0.0%
EPS Growth
+42.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -97K | 0 | 0 | 0 | 0 |
| Operating Income | -68M | -82M | -40M | -45M | -36M |
| EBITDA | -68M | -30M | -40M | -45M | -36M |
| Net Income | -60M | -74M | -35M | -45M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36M | 87M | 93M | 44M | 47M |
| Total Assets | 168M | 217M | 110M | 135M | 173M |
| Total Liabilities | 7M | 5M | 3M | 6M | 6M |
| Shareholder Equity | 160M | 212M | 108M | 129M | 167M |
| Total Debt | 541K | 532K | 349K | 480K | 0 |
| Net Debt | -35M | -87M | -93M | -43M | -47M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
36M
+3.5% YoY
Capital Expenditures
0
Free Cash Flow
36M
+3.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-33.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.